After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved swiftly to shore up its finances with a $225 million second round to fund the developme
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.